Chalcone 4 is a potent, selective inhibitor of the chemokine CXCL12 via direct binding. It is also a small molecule anti-ligand (or neutraligand) of CXCR4 and CXCR7.
Chalcone 4 is a potent, selective inhibitor of the chemokine CXCL12 via direct binding. It is also a small molecule anti-ligand (or neutraligand) of CXCR4 and CXCR7. The chemokine CXCL12 (stromal cell-derived factor-1) and its receptors play pivotal roles in inflammatory responses, normal vascular and neuronal development, as well as in infectious diseases and cancer. Chalcone 4 binds to and activates the chemokine receptors CXCR4 and CXCR7 and stimulates a rapid receptor-mediated intracellular calcium mobilization and signaling through a Pertussis toxin sensitive Gi protein. Chalcone 4 potently and selectively inhibits CXCL12 binding to CXCR4 and CXCR7, and consequent CXCL12-evoked calcium cellular responses. Chalcone 4 binds to the chemokine CXCL12, but not to its receptors.
Features and Benefits
This compound is featured on the Chemokine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Journal of medical screening, 21(2), 71-75 (2014-03-14)
To establish the reliability and validity of an automated hearing screening test system for preschoolers and to investigate the risk factors for hearing loss. The study used a cross-sectional design in a comparative study of subjects. The automated hearing screening
Hypertension research : official journal of the Japanese Society of Hypertension, 37(6), 538-542 (2014-03-14)
The aim of this study was to determine the predictive value of the combination of plasma-soluble fms-like tyrosine kinase 1 (sFlt-1) and uterine artery Doppler for the detection of preeclampsia in women of advanced age at 16-18 weeks of gestation
Testing for ALK rearrangements in advanced, non-squamous non-small-cell lung cancers that are wild-type for activating EGFR mutation has become standard care. Fluorescence in-situ hybridization is considered the gold standard for this evaluation. Pre-screening with immunohistochemistry has been suggested, to reduce
Clinical drug investigation, 34(6), 373-382 (2014-03-14)
GC1113, a hybrid Fc-fused erythropoietin, is a novel erythropoiesis-stimulating agent that is expected to have an extended duration of action. The preclinical data showed that the hemoglobin increase lasted longer following GC1113 administration than it did following the administration of
This study introduces and validates the Hip Lag Sign, a new clinical parameter to determine hip abductor damage, which appears to be one major cause for greater trochanteric pain syndrome. 26 patients who underwent standardized MRI-examination were prospectively enrolledbetween October
We offer many products related to chemokine receptors for your research needs.
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
